SNM Annual Meeting Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     



J Nucl Med. 2008; 49 (Supplement 1):168P
This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Penate, O.
Right arrow Articles by Larson, S.
PubMed
Right arrow Articles by Penate, O.
Right arrow Articles by Larson, S.

Novel Approaches to Molecular Imaging

Novel Approaches to Molecular Imaging Posters

Tumor imaging by using a combination of positron labeled EGFR tyrosine kinase inhibitors and stealth nanocarriers

Oula Penate1, Athanasios Glekas1, Nagavarakishore Pillarsetty1, Valerie Longo1, Blesida Punzala1, Pat Zanzonico1, Peter Smith-Jones1 and Steve Larson1

1 Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York


Formula

733

Objectives: PET with epidermal growth factor receptor (EGFR) kinase-specific radiolabeled tracers could provide the means for imaging of EGFR expression and signaling activity in tumors in patients during therapy with EGFR inhibitors. Our group has develop PET tracers irreversibly binding to EGFR, However because of significant hepatobiliary clearance and intestinal reuptake of the morpholino-[124I]-IPQA (SKI212243) and overall hydrophobicity with octanol water coeeficients of up to 4, additional formulation steps are needed for optimization of the pharmacokinetics of these imaging agents. Thus these drugs are interesting candidates for utilizing lipid base nanoparticles, which improve the solubility of the drugs but also increase the circulation time in the blood stream and spontaneously target to the tumors. In our work we compared the combined targeting approach by using EGFR kinase targeting SKI212243 (SKI243) embedded in liposomes and bare SKI243 as a PET tracer.

Methods: EGFR inhibitors were encapsulated in to PC/chol/PEG-PE liposomes of 100nm. PET imaging of Nude mice bearing A431 and H3255 was done in 0.25, 1, 2, 24, 48, 72 h time points by using MicroPET. Biodistribution of the SKI243 was measured with imaging agent and liposomal imaging agent.

Results: SKI243 and liposomal SKI243 are taken up to the tumor. Liposomal drug stays longer in the blood and consequently increase the tumor uptake. We found that uptake in tumor could be increased 3-6 fold with the use of liposomal nanocarriers, although liver and lungs also show some increased uptake.

Conclusions: Liposomal formulation of SKI243 appears promising to enhances the in vivo efficiency in tumor imaging by significantly increasing the targeting of lipophilic tyrosine kinase inhibitor drugs.





This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Penate, O.
Right arrow Articles by Larson, S.
PubMed
Right arrow Articles by Penate, O.
Right arrow Articles by Larson, S.